Skip to main content
USPH logo

U.S. Physical Therapy, Inc. (USPH) Stock: Price, Forecast & Analyst Target

U.S. Physical Therapy, Inc. (USPH) — MoonshotScore 62/100 (Fair band), calculated Oct 4, 2026. Price $83.72 (+1.36%), as of the Oct 2, 2026 trading session; market cap $1.27B.

Educational signal · not a buy or sell recommendation · How to read this

$83.72 +$1.12 (+1.36%) Market Cap $1.27B

U.S. Physical Therapy, Inc. · USPH · NYSE

U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics and provides industrial injury prevention services.

Price as of Oct 2, 2026

Key Statistics

62 of 100

MoonshotScore v2 · U.S. Physical Therapy (USPH)

Fair
Business Quality Solid (70)
Financial Safety Strained (22)
Valuation Fair (67)
Growth Durability Flat (52)
Momentum Rising (77)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Rising.

  • quarterly revenue $214M (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 3 of 8
  • Altman Z 2.68 · Piotroski F 5

Holding back: balance-sheet strain

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for USPH (29 recorded, newest six shown)
RecordedScoreBand
62Fair
62Fair
62Fair
62Fair
62Fair
62Fair

The score was 62 in the stored Oct 3, 2026 snapshot and remains 62 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Business Quality +1 and Valuation +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$83.72
Change on the day+1.36%
52-week range$58.19 – $93.50
Market capitalisation$1.27B
Price / earnings (trailing)492.47
Shares traded on the day235.7K

Price & events

Other perspectives

Council score for U.S. Physical Therapy (USPH): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

9-Factor Breakdown

Revenue Growth Neutral
Gross Margin Neutral
Operating Leverage Neutral
Cash Runway Neutral
R&D Intensity Neutral
Insider Activity Moderate
Trading Liquidity Neutral
Price Momentum Negative
News Sentiment Neutral

Legends Council

0 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Read date unavailable · not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Weak
ROE Weak
Gross Margin Weak

Read on: Apr 30, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 30, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the USPH film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is U.S. Physical Therapy (USPH), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. U.S. Physical Therapy, Inc. (USPH) is listed on NYSE. It employs 6,374 people and is led by Christopher J. Reading. In Q2 FY2026 it reported revenue of $214M and net income of $2M. The market values it at $1.27B.

2 · Latest results

What do the latest results show for U.S. Physical Therapy (USPH)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $214M. Against analyst estimates the company has EPS beat 3 of 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$214M$2M$0.25 (diluted)
Q1 FY2026$198M-$4M-$0.12 (diluted)
Q4 FY2025$203M-$11M-$0.44 (diluted)
Q3 FY2025$164M$7M$0.48 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for U.S. Physical Therapy (USPH)?

Short answer

The MoonshotScore pillars rate business quality, positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 2.68 · Piotroski F 5. Trailing ratios: ROE 6.5% · ROA 4.1% · current ratio 1.27.

4 · What to check next?

What should you watch next at U.S. Physical Therapy (USPH)?

Short answer · as of

Current published price targets run low $90.00 · high $90.00 · consensus $90.00 · median $90.00 against a quoted price of $83.72 (as of Oct 2, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does U.S. Physical Therapy compare with its peers?

Short answer

U.S. Physical Therapy's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
National HealthCare Corporation (NHC) Named competitor$227.66 Oct 2, 2026$3.56B98 5-pillar Oct 4, 2026
AMN Healthcare Services, Inc. (AMN) Same industry, near in market value$36.63 Oct 2, 2026$1.42B95 5-pillar Oct 4, 2026
Healthcare Services Group, Inc. (HCSG) Same industry, near in market value$20.87 Oct 2, 2026$1.43B94 5-pillar Oct 4, 2026
Addus HomeCare Corporation (ADUS) Same industry, near in market value$111.27 Oct 2, 2026$2.08B93 5-pillar Oct 4, 2026
Pediatrix Medical Group, Inc. (MD) Same industry, near in market value$25.97 Oct 2, 2026$2.13B90 5-pillar Oct 4, 2026
Omnicell, Inc. (OMCL) Named competitor$33.60 Oct 2, 2026$1.53B84 5-pillar Oct 4, 2026
Ardent Health Partners, LLC (ARDT) Same industry, near in market value$10.34 Oct 2, 2026$1.48B76 5-pillar Oct 4, 2026
Astrana Health, Inc. (ASTH) Same industry, near in market value$35.88 Oct 2, 2026$1.78B75 5-pillar Oct 4, 2026
ATI Inc. (ATI) Named competitor$192.42 Oct 2, 2026$26.3B70 5-pillar Oct 4, 2026
The Pennant Group, Inc. (PNTG) Same industry, near in market value$39.24 Oct 2, 2026$1.36B70 5-pillar Oct 4, 2026
U.S. Physical Therapy (USPH) — this page$83.72$1.27B62
InnovAge Holding Corp. (INNV) Same industry, near in market value$8.96 Oct 2, 2026$1.22B39 5-pillar Oct 4, 2026
Agilon Health, Inc. (AGL) Same industry, near in market value$84.14 Oct 2, 2026$1.40B33 5-pillar Oct 4, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$90.00 – $90.00
Consensus target
$90.00
Median target
$90.00

Consensus record · Captured .

Measured against a quoted price of $83.72 (as of Oct 2, 2026).

Insider activity

Form 4 records via FMP · Available records within the last 180 days, newest dated Sep 14, 2026 (coverage not recorded)

Transactions
21
Identified insiders
10
Purchases
4
Sales
0
Other transactions
17

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

What has been published about U.S. Physical Therapy (USPH)?

Read these with our analysis →

Common Questions About USPH

These answers are editorial: 1 of these 9 answers is drawn from the USPH research dossier (written May 7, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for USPH?

USPH carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is USPH a good stock to buy?

Stock Expert AI does not rate USPH buy, sell or hold. U.S. Physical Therapy, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the USPH stock price today?

The last price recorded on this page for U.S. Physical Therapy, Inc. (USPH) is $83.72, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the USPH price target?

The analyst consensus price target for U.S. Physical Therapy, Inc. (USPH) is $90.00 (range $90.00 to $90.00, median $90.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for USPH?

U.S. Physical Therapy, Inc. faces several risks, including competition from other physical therapy providers, changes in reimbursement policies and rates, economic downturns affecting patient demand, rising operating costs, and regulatory changes in the healthcare industry.

What are the key factors to evaluate for USPH?

U.S. Physical Therapy, Inc. (USPH) holds a MoonshotScore in the moderate range. P/E: 492.47x. Analysts target $90.00 (+8%). Not financial advice.

How frequently does USPH data refresh on this page?

USPH's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven USPH's recent stock price performance?

U.S. Physical Therapy, Inc. (USPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider USPH overvalued or undervalued right now?

U.S. Physical Therapy, Inc. (USPH) trades at 492.47x earnings. Analysts target $90.00 (+8%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 7, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (22 figures)

The 22 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 14 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$83.72FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T23:04:48.743Z.
px.changeChange on the day+1.36%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$1.27BFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:03.000Z. Captured from FMP at 2026-10-04T23:04:45.305Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars+$1.12FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q2 FY2026$214MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.pePrice / earnings (trailing)492.47FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day235.7KFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q2 FY2026$2MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q2 FY2026FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed
earn.ptStored analyst price targetslow $90.00 · high $90.00 · consensus $90.00 · median $90.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_rangeAnalyst price target, low to high$90.00 – $90.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_consensusConsensus analyst price target$90.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_medianMedian analyst price target$90.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
own.insidersInsider transactions via FMP21 transactions · 4 purchases, 0 sales, 17 other transactions · 10 identified insiders · available records within the last 180 days, newest dated Sep 14, 2026 (coverage not recorded)FMPFinancial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

UNRECORDED — 6 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 3 of 8UNRECORDEDStored earnings-history observation — Captured 2026-10-04
fin.scoresDistress and quality screensAltman Z 2.68 · Piotroski F 5UNRECORDEDStored financial-scores observation — Captured 2026-10-04
px.range5252-week range$58.19 – $93.50UNRECORDEDStored company-profile observation — Captured 2026-10-04
id.employeesEmployees6,374UNRECORDEDStored company-profile observation — Captured 2026-10-04
id.ceoChief executiveChristopher J. ReadingUNRECORDEDStored company-profile observation — Captured 2026-10-04
fin.ratiosReturn and yield ratios (trailing twelve months)ROE 6.5% · ROA 4.1% · current ratio 1.27—UNRECORDEDStored key metrics — Date unknown

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v262 of 100 · Fair · pillars 70 / 22 / 67 / 52 / 77OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement62 (stored snapshot Oct 3, 2026) → 62 (current publication computed Oct 4, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.